07:58 AM EDT, 04/04/2024 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) said Thursday that it has begun a process with US and Canadian health regulators to voluntarily discontinue the marketing authorizations for its amyotrophic lateral sclerosis drug Relyvrio, which is sold in Canada under the name Albrioza.

The drugs will no longer be available for new patients as of Thursday, and patients currently using the therapy in the US and Canada can be transitioned to a free drug program.

The pharmaceutical company said the removal of the drug from US and Canadian markets is based on topline results released last month from a phase 3 trial that failed to meet the primary and secondary endpoints at week 48.

Amylyx also said Thursday that it will reduce its workforce by approximately 70% and decrease external financial commitments outside of its priority areas.

Price: 2.65, Change: +0.02, Percent Change: +0.76